| TGA Action ID |
RC-2026-RN-00744-1 |
| Type of Product |
Medicine |
| Product Name/Description |
Cefazolin 6,000mg in 0.9% Sodium Chloride in Surefuser + (10mL/hr) for Intravenous Infusion
Batch Number: BB260819555
Expiry: 23/11/2026
ARTG Exempt |
| ARTG Number |
|
| Unique Device Identifier (UDI) |
BB260819555 |
| Action Type |
Recall |
| Action Level |
Hospital |
| Hazard Classification |
Class II |
| Reason for the Action |
Upon receipt of the compounded product, the customer identified a defective line which was cut, preventing infusion from occurring. No leaking had occurred within the inner clear protective bag. All other units from batch BB260819555 were not impacted and were still fit for use.
Given the nature of the product, this action was undertaken prior to TGA notification (Immediate Market Action as defined within the PRAC). |
| Instructions for Customers/Users |
The severed line was identified prior to use, and the product was discarded by the treating clinician. |
| Action Commencement Date |
25/09/2026 |
| Responsible Entity |
|
| Contact Information |
(03) 9565 4300 - Slade Health Head Office |